FDA Found Repeat Deficiencies at Valsartan Manufacturer’s Facility

Drug GMP Report
In another twist in the worldwide recall of the contaminated blood pressure medication, valsartan, the FDA released two Form 483 reports issued to the API’s manufacturer in China after inspections in 2016 and 2017.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $157.00